WuXi AppTec Co., Ltd. (WUXIF)
ValueMarkers Composite Index
174% above intrinsic value ($1)
WuXi AppTec Co., Ltd. (WUXIF) — VMCI valuation read
Across 120 indicators, WuXi AppTec Co., Ltd. (WUXIF) lands at VMCI 66/100. The Healthcare sector median is 50, so the 16-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.
No material Form 4 disclosures landed on WUXIF in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.
**Investor frame.** On Value, WUXIF trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 2.0x is the rate-sensitivity line to watch for WUXIF on the trailing balance sheet.
WUXIF fell 1.4% over the trailing 7 days, with a +6.4% read on a 30-day basis.
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.